Caplight Directory>Companies>Transcend Biologics-preview>Transcendbiologics


Transcend Biologics

Transcend Biologics

Private
The Colony, TexasN/Ahttps://transcendbiologics.com/

Last Round

M&A

Mar 27, 2026

Est. Valuation

$1.23B

Total Funding Raised

$41.5M

Company Overview

Transcend Biologics is a medical technology company that develops and distributes platelet-rich plasma (PRP) solutions for medical and veterinary professionals.

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Transcend Biologics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Transcend Biologics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
M&AMar 27, 2026
Series AFeb 23, 2023
SeedDec 17, 2021
View all Funding Rounds

Key People

Founding team and executive leadership

Paul O'Brien

Chief Executive Officer

Executive Team

Transcend Biologics Investors

Notable investors and investment history

InvestorRounds
AlleyCorpSeries A, Seed
Emerald Development ManagersSeries A
IntegratedSeries A
Global Founders CapitalSeries A
Otsuka PharmaceuticalM&A
Alpha Wave GlobalSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 27, 2026

    $700M raised with Otsuka Pharmaceutical

  • Jan 21, 2026

    Monthly visitors increased 39% MoM, reaching 2.7K.

View all signals

Transcend Biologics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Transcend Biologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Transcend Biologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersThe Colony, Texas
Employee Range7
Year Founded2021
Last FundingMar 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.